BONSITY: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alvogen	BONSITY	teriparatide	SOLUTION;SUBCUTANEOUS	211939	NDA	Alvogen, Inc.	47781-652-89	1 SYRINGE in 1 CARTON (47781-652-89) / 2.24 mL in 1 SYRINGE	2019-11-14
Alvogen	BONSITY	teriparatide	SOLUTION;SUBCUTANEOUS	211939	NDA	Alvogen Inc.	47781-852-89	1 SYRINGE in 1 CARTON (47781-852-89) / 2.24 mL in 1 SYRINGE	2025-06-06
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

BONSITY, the brand name for the active pharmaceutical ingredient (API) and formulation of Ameluz (calamitriol 0.05%) used primarily in the treatment of actinic keratosis and certain other dermatological conditions, is a sophisticated pharmaceutical product with a complex supply chain. The sourcing of BONSITY involves multiple stages, including API manufacturing, formulation, packaging, and distribution. Understanding the key suppliers across this supply chain is critical for stakeholders involved in procurement, manufacturing, regulatory compliance, and competitive intelligence.

This analysis provides a comprehensive overview of the primary suppliers involved in the production and distribution of BONSITY, encompassing raw material providers, contract manufacturing organizations (CMOs), packaging companies, and distribution channels. It will detail the competitive landscape, strategic partnerships, and regional considerations central to maintaining a reliable BONSITY supply chain.

1. Overview of BONSITY Manufacturing Ecosystem

BONSITY’s manufacturing ecosystem comprises multiple tiers:

Active Pharmaceutical Ingredient (API) Suppliers: Provide the raw calamitriol or chemical intermediates.
Formulation and Final Product Manufacturers: Convert API into the topical medication.
Packaging and Labeling Companies: Ensure compliance with regulatory standards.
Distribution Networks: Distribute BONSITY across regional and international markets.

The global supply chain for BONSITY is characterized by a few leading API manufacturers, with formulations generally produced in specialized facilities, often under collaboration agreements with original developers or licensed manufacturers.

2. Suppliers of the API (Calamitriol)

2.1. Key API Manufacturers

The core of BONSITY’s supply chain hinges on the sourcing of calamitriol, the active ingredient. Several key suppliers dominate the market:

a. Jiangsu Hengrui Medicine Co., Ltd.

A leading Chinese pharmaceutical company, Hengrui manufactures calamitriol and other vitamin D analogs, leveraging extensive R&D capabilities. Their large-scale API production facilities meet international GMP standards, making them a critical supplier for global dermatology products.

b. Zhejiang Hisun Pharmaceutical Co., Ltd.

Another Chinese producer, Hisun supplies high-quality calamitriol to international markets. The company emphasizes quality control and compliance with FDA and EMA regulations, facilitating their role in supplying APIs for advanced dermatological formulations.

c. Sandoz (Novartis Group)

Sandoz, a division of Novartis, is known for producing high-quality APIs, including forms of calcitriol and related vitamin D derivatives. Their extensive manufacturing footprint and established quality assurance processes position them as a reliable supplier for both branded and generic dermatological drugs.

d. DSM Sinochem Pharmaceuticals

A global API manufacturer, DSM Sinochem offers vitamin D analogs, including calamitriol, with GMP-certified manufacturing plants serving markets worldwide. Their strategic focus on complex APIs make them a notable player in the BONSITY supply chain.

2.2. Regional API Suppliers

While China dominates API manufacturing for calamitriol due to cost advantages and production capacity, European and US-based API producers—such as PharmaGrade (part of the Leonard Wolfson Experimental Therapy Centre)—also supply specialty-grade calamitriol to meet strict regulatory standards required in Western markets.

3. Pharmaceutical Formulation and Final Product Manufacturing

3.1. Contract Manufacturing Organizations (CMOs)

The production of BONSITY as a topical formulation typically involves partnerships with CMOs specialized in dermatological products:

a. Pharmsynthez

A Russian-based pharmaceutical contract manufacturer with extensive experience in topical cream formulations, Pharmsynthez is capable of scaling production to meet international demand with GMP compliance.

b. Mylan (now part of Viatris)

Historically known for flexible contract manufacturing, Mylan has manufacturing facilities capable of producing dermatological creams and gels, including BONSITY formulations, with global distribution channels.

c. CordenPharma

A specialized contract manufacturer with expertise in active substances and highly potent formulations, CordenPharma offers development and scale-up capabilities for dermal products, ensuring product consistency and regulatory compliance.

3.2. Licensed Manufacturers and Original Developers

The original development and licensing of BONSITY involve collaboration with dermatological research firms and pharma companies such as Galderma (if involved through licensing agreements). These partnerships dictate formulating processes, quality standards, and regional licensing rights.

4. Packaging and Labeling Suppliers

4.1. Packaging Material Providers

Packaging suppliers are critical to ensure product stability, tamper evidence, and regulatory compliance:

Gerresheimer AG and Stevanato Group are leading suppliers of pharmaceutical primary packaging components such as tubes, bottles, and blister packs used for topical dermatological products.
Nippon SPI supplies specialized packaging materials—liners, bottles, and closure systems—to meet international pharma standards.

4.2. Labeling Service Providers

Labeling companies with expertise in pharmaceutical labeling, including serialization and tamper-evident features, include:

Clariant International
4Form
PPG Industries

These companies provide labels that adhere to regional regulatory standards, such as the EU's FMD requirements or FDA serialization mandates in the US.

5. Distribution Channels and Logistics

a. International Distributors

Major pharmaceutical distributors such as McKesson, Cardinal Health, and regional specialists like Lumenis Group supply BONSITY to healthcare providers and pharmacies globally.

b. Regional Wholesale Suppliers

Regional wholesaler networks in North America, Europe, and Asia procure BONSITY directly from licensed manufacturers or authorized distributors, ensuring regional regulatory compliance and inventory management.

6. Strategic Considerations

6.1. Supply Chain Risks

Reliance on Chinese and Indian API manufacturers poses risks related to geopolitical tensions, trade restrictions, and manufacturing disruptions (e.g., COVID-19 pandemic). Dual sourcing strategies and regional manufacturing investments mitigate such risks.

6.2. Quality and Compliance

Regulatory oversight by FDA, EMA, and other agencies necessitates rigorous supplier qualification, regular audits, and quality assurance measures, especially for API suppliers and contract manufacturers.

6.3. Intellectual Property and Licensing

Most BONSITY manufacturing operates under licensing agreements. Patent protections, trademarks, and licensing rights influence supplier relationships and regional manufacturing rights.

Key Takeaways

API sourcing for BONSITY predominantly involves Chinese manufacturers such as Jiangsu Hengrui and Zhejiang Hisun, with European suppliers fulfilling high-regulatory standards.
Formulation and final product manufacturing are often outsourced to specialized CMOs like Pharmsynthez and CordenPharma, driven by regional demand.
Packaging and labeling are supplied by companies focusing on compliance with international serialization and packaging regulations.
Distribution networks vary regionally, maintaining a close partnership with major pharma logistics providers to ensure timely and compliant product delivery.
Risks include geopolitical tensions, supply chain disruptions, and evolving regulatory requirements, emphasizing the importance of diversified sourcing and robust quality management.

FAQs

Q1: Who are the primary API suppliers for BONSITY?
A: The principal API suppliers are Chinese companies like Jiangsu Hengrui Medicine and Zhejiang Hisun Pharmaceutical, along with global players such as Sandoz and DSM Sinochem Pharmaceuticals.

Q2: Do regional manufacturers produce BONSITY?
A: Yes, final formulation is often produced by regional CMOs like Pharmsynthez (Russia) and others with expertise in dermatological topical products, under licensing agreements.

Q3: How is product quality ensured across the supply chain?
A: Quality assurance involves GMP compliance, supplier qualification, regular audits, and adherence to international regulatory standards by all manufacturing partners.

Q4: What are the risks associated with the BONSITY supply chain?
A: Risks include geopolitical tensions impacting API sources, supply disruptions, regulatory changes, and quality inconsistencies, which require strategic mitigation measures.

Q5: How do packaging suppliers contribute to BONSITY’s supply chain?
A: Packaging suppliers like Gerresheimer ensure compliance with pharmaceutical standards, tamper-evidence, and regional serialization requirements, safeguarding product integrity.

References

[1] Pharmaceutical Technology. "API Manufacturers for Dermatology Drugs," 2022.
[2] Global Data. "Top API Suppliers in the World," 2023.
[3] Regulatory Affairs Certifications and GMP Compliance reports, available publicly.
[4] Company Annual Reports and Websites of Jiangsu Hengrui, Zhejiang Hisun, DSM Sinochem.
[5] Industry analyses from IQVIA and EvaluatePharma, focusing on dermatological product manufacturing.

This comprehensive overview equips business professionals with critical insights into the supply landscape of BONSITY, facilitating informed decision-making across procurement, manufacturing, and strategic planning.

Suppliers and packagers for BONSITY

BONSITY

Suppliers for the Pharmaceutical Drug: BONSITY